Anuh Pharma Ltd
Know More148.00↑-1.05 (-0.70%)
04:01 PM,7th Dec 2023BSE : 506260
NSE :
Sector : Health care
ISIN Code : INE489G01022
- NSE
- BSE
- 1D
- 5D
- 1M
- 6M
- 1Y
- 2Y
- 5Y
- MAX
Last Updated: Dec 07 2023 | 04:01 PM IST
| Market Cap (₹ Cr) | 0 |
Turnover (₹ Cr) | 0.00 |
Volume (Shares) | |
Face Value | 5 |
52-WK High | 0.00 |
52-WK High Date | Invalid date |
52-WK Low | 0.00 |
52-WK Low Date | Invalid date |
All Time High | 0.00 |
All Time High Date | Invalid date |
All Time Low | 0.00 |
All Time Low Date | Invalid date |
Anuh Pharma Ltd
Anuh Pharma Ltd is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company offers bulk drugs and chemicals. Their products are antibiotics erythromycin salts chloramphenicol and other chemicals. The company is part of the SK Group.Anuh Pharma Ltd was incorporated on February 19 1960. The company is well positioned to service their existing and potential markets through their manufacturing operations at Tarapur in Maharashtra. All the facilities are built and operated according to cGMP. They also received plant approvals from several MNCs.The business headquarters of the firm is located in the commercial capital of India Mumbai. The company is a recognized export house and exports their products to Mexico Brazil Iran Bangladesh Colombia Germany Africa Singapore and several other countries.During the year 2006-07 the company commissioned the new plant with all latest modern techniques and facilities. Thus the production capacity of Antibiotics increased from 400000 Kg to 600000 Kg.During the year 2008-09 the company completed the on-going expansion of their plant thus they increased the installed capacity by 150 MT per annum. In September 2008 they expanded unit started commercial production.In January 2010 the company received approval for their product Erythromycin E.P. from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Erythromycin E.P. in European counties for their own consumption.In April 2010 the company received approval for their product Pyrazinamide from European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval paves the way for the company to sell Pyrazinamide in European countries for their own consumption.In June 2010 the company received approval for their product Clobetasol Propionate from European Directorate for the Quality Medicines & Healthcare. This approval paves the way for the company to sell Clobetasol Propionate in European counties for their own consumption.
News
View MoreAnnouncement
View MoreAnuh Pharma Ltd - Key Fundamentals
| PARAMETER | VALUES |
|---|---|
| Market Cap (₹ Cr) | 741 |
| EPS - TTM (₹) [S] | 8.88 |
| P/E Ratio (X) [S] | 2.89 |
| Face Value (₹) | 5 |
| Latest Dividend (%) | 40.00 |
| Latest Dividend Date | 11 Aug 2023 |
| Dividend Yield (%) | 1.35 |
| Book Value Share (₹) [S] | 51.23 |
| P/B Ratio (₹) [S] | 2.89 |
| [*C] Consolidated [*S] Standalone | |
Funds Owing this Stock
| Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 0.00 | 148 | 0.03 |
Research Reports
| Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
|---|---|---|---|---|
| Data Not Found |
Stock Strength
| Today's Low/High | 146.80 151.00 |
| Week Low/High | 146.80 162.00 |
| Month Low/High | 125.00 172.00 |
| Year Low/High | 77.00 172.00 |
| All time Low/High | 0.14 219.00 |
Share Price Returns
| Period | BSE | NSE | SENSEX | NIFTY |
|---|---|---|---|---|
| 1 Week | -6.00% | % | 3.78 | 3.81% |
| 1 Month | 16.63% | % | 7.05 | 7.70% |
| 3 Month | 10.41% | % | 4.91 | 5.95% |
| 6 Month | 65.05% | % | 10.72 | 12.38% |
| 1 Year | 60.87% | % | 11.39 | 12.61% |
| 3 Year | 5.23% | % | 53.04 | 56.50% |
Company Info
Company Information
Vice Chairman : Bipin N Shah
Non-Exec & Non-Independent Dir : Bharat N Shah
Non-Exec. & Independent Dir. : Arun L Todarwal
Non-Exec & Non-Independent Dir : Samir J Shah
Non-Exec & Non-Independent Dir : Ketan L Shah
Joint Managing Director : Ritesh B Shah
Joint Managing Director : Vivek B Shah
Chairman & Independent Directo : Jasvantlal Shah
Non-Exec & Non-Independent Dir : Mita Dixit
Non-Exec. & Independent Dir. : Harmanbhai Tulsibhai Patel
Non-Exec. & Independent Dir. : Sandeep M Joshi
Company Sec. & Compli. Officer : Hemant Auti
Independent Director : Pradeep Thakur
Independent Director : Siddharth Shah
Independent Director : Gaurav Shah
Registered Office: 3-A Shivsagar Estate, North Wing Dr A B Road Worli,Mumbai,Maharashtra-400018 Ph: 91-22-6622 7575
Email:anuh@sk1932.com
